Table 2 Pairwise comparisons of ORR in different chemotherapy regimens

From: Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry

  

ORR

P -value

Oxaliplatin vs cisplatin doublets

IT

44.4% vs 28.5%

1.0000

 

DT

40.7% vs 34.0%

0.1692

Anthracyclines vs platinum–fluoropyrimidine doublets

IT

60.0% vs 37.5%

0.0048

 

DT

40.8% vs 36.7%

1.0000

Docetaxel vs platinum–fluoropyrimidine doublets

IT

61.5% vs 37.5%

0.0124

 

DT

51.0% vs 36.7%

0.3796

Docetaxel vs anthracyclines

IT

61.8% vs 60.0%

0.8597

 

DT

51.0% vs 40.8%

0.9791

  1. Abbreviations: DT=diffuse type; IT=intestinal type; ORR=overall response rate. Data set: subjects with response-evaluable (at 3 months) and initially measurable disease (n=730). Test used: χ2; P-values were corrected using the Holm–Bonferroni method.
Back to article page